LV11869B - Culture medium for trichomonas vaginalis - Google Patents
Culture medium for trichomonas vaginalis Download PDFInfo
- Publication number
- LV11869B LV11869B LVP-97-12A LV970012A LV11869B LV 11869 B LV11869 B LV 11869B LV 970012 A LV970012 A LV 970012A LV 11869 B LV11869 B LV 11869B
- Authority
- LV
- Latvia
- Prior art keywords
- acid
- medium
- bail
- culture medium
- culture
- Prior art date
Links
- 239000001963 growth medium Substances 0.000 title claims abstract description 10
- 241000224527 Trichomonas vaginalis Species 0.000 title abstract description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 16
- 229960005322 streptomycin Drugs 0.000 claims abstract description 10
- 102000016943 Muramidase Human genes 0.000 claims abstract description 9
- 108010014251 Muramidase Proteins 0.000 claims abstract description 9
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 9
- 239000012153 distilled water Substances 0.000 claims abstract description 9
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 9
- 239000004325 lysozyme Substances 0.000 claims abstract description 9
- 229960000274 lysozyme Drugs 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 8
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 8
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 8
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 229960005010 orotic acid Drugs 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 241000224526 Trichomonas Species 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- SMHNUIFHMAGAFL-UHFFFAOYSA-N calcium;2-hydroxypropanoic acid Chemical compound [Ca].CC(O)C(O)=O SMHNUIFHMAGAFL-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000010454 slate Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 6
- 238000000605 extraction Methods 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 3
- 229930182555 Penicillin Natural products 0.000 abstract description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract description 2
- 229940049954 penicillin Drugs 0.000 abstract description 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 abstract 1
- 229960002401 calcium lactate Drugs 0.000 abstract 1
- 235000011086 calcium lactate Nutrition 0.000 abstract 1
- 239000001527 calcium lactate Substances 0.000 abstract 1
- 229960002086 dextran Drugs 0.000 abstract 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
- 229960005419 nitrogen Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 244000247617 Teramnus labialis var. labialis Species 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003771 laboratory diagnosis Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 206010046704 Urogenital trichomoniasis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Izgudrojums attiecas uz medicīnu tai skaitā uz medicīnisko mikrobioloģiju un laboratoriskās diagnostikas specialitāti, bet tieši uz ginekoloģiju, veneroloģiju un uroloģiju. Izgudrojums var tikt izmantots Trichomonas vaginalis izraisītu slimību laboratoriskai diagnostikai.The invention relates to medicine, including medical microbiology and laboratory diagnostics, but specifically to gynecology, venerology and urology. The invention can be used for laboratory diagnosis of diseases caused by Trichomonas vaginalis.
Urīnceļu un dzimumorgānu iekaisuma slimības starp daudziem vīrusiem un baktērijām izraisa arī vienšūnu organisms - Trichomonas vaginalis, kuras patogēnas cilvēkiem un lokalizējas uroģenitālas orgānos. Klīniskās norises agresivitāti makroorcanismā veicina dažādi ekzoģenētiskie un endoģenētiskie faktori, ka arī slimības izraisītāja virulence. Izmeklējot slimniekus ar urincelu un dzimumceļu orgānu iekaisuma slimībām, kas pieder pie seksuālās transmisijas slimību grupas, trihomonas konstatē līdz 32% gadījumos sievietēm un 53% - vīriešiem.Inflammatory diseases of the urinary tract and genital organs among many viruses and bacteria are also caused by a single-celled organism, Trichomonas vaginalis, which is pathogenic to humans and localizes in the urogenital organs. Various exogenous and endogenous factors, as well as virulence of the disease agent, contribute to the aggressiveness of the clinical course in macro-cancer. Trichomonas is found in up to 32% of women and 53% of men in patients with inflammatory diseases of the urinary tract and genital organs of the sexually transmitted diseases.
Trichomonas ir fakultatīvi anaerobi mikroorganismi, barojas endoosmatiski, uzsūcot barības vielas no apkārtējās vides caur šūnas apvalka virsmu. Tās vairojas temperatūrā 35-37° C pie pH 5,5 - 7,5.Trichomonas are optional anaerobic microorganisms that feed endosmatically by absorbing nutrients from the environment through the surface of the cell envelope. They multiply at 35-37 ° C at pH 5.5 - 7.5.
Klīniskā praksē ir svarīgi zināt, kādas attiecības izveidojas starp Trichomonas vaginalis un urogenitālos orgānos esošu asociētu mikrofloru, piemēram, gonokokiem, hlamīdijām, mikoplazmām, ureaplazmām, kandidām utt. Mikroorganismu dažādas kombinācijas ietekmē slimības norises klīnisko gaitu, ārstēšanas metodes izvēli un pretepidemioloģiskus pasākumus. Uroģenitālo orgānu slimības kā mikstinfekcija noris 80 - 35% gadījumu. Trichomonas var būt arī kā rezervuārs citiem mikroorganismiem, piemēram, tajās var dzīvot un vairoties gonokoki.In clinical practice, it is important to know the relationship between Trichomonas vaginalis and the associated microflora in the genitourinary organs, such as gonococci, chlamydia, mycoplasma, ureaplasma, candidiasis, etc. Different combinations of microorganisms influence the clinical course of the disease, the choice of treatment method and the anti-epidemiological measures. Urogenital diseases such as microbial infections occur in 80-35% of cases. Trichomonas can also serve as a reservoir for other microorganisms, such as gonococci, which can live and reproduce.
Lai optimizēt uroģenitālo Trichomonu izraisītu slimību ārstēšanu, īpaši svarīgi pielietot jūtīgas un specifiskas uroģenitālās irichomoniāzes laboratoriskās diagnostikas metodes. Visspecifiskākā un pietiekoši jūtīga uroģenitālās trichoraoniāzes laboratoriskās diagnostikas metode ir Trichomonas vaginalis kultivēšana barotnē jeb kultūrdiagnostika, kura dod iespēju izdalīt Trichomonas vaginalis tīru kultūru ar sekojošu tās mikroskopiju. Par izmeklēšanas materiālu izmanto no uroģenitālā trakta redzamo gļotādu un tūpļa pataloģisko perēkļu virsmasIn order to optimize the treatment of urogenital Trichomoniasis diseases, it is particularly important to use sensitive and specific laboratory diagnostic methods for urogenital irichomoniasis. The most specific and sufficiently sensitive method of laboratory diagnosis of urogenital trichoraoniasis is the cultivation of Trichomonas vaginalis in culture medium or culture diagnostics, which allows the isolation of pure culture of Trichomonas vaginalis by subsequent microscopy. Surface material of the mucous membrane of the urogenital tract and of the anus of the anus is used as examination material
-2pa»emtos paraugus ( 1,2 ). Klīnisku provju iegūšanai ieteicams izmantot speciālu instrumentu - ierīce caurulveida orgānu satura izņemšanai (3).-2pa »samples taken (1,2). The use of a special instrument, the tubular organ removal device (3), is recommended for clinical examination.
Lai iegūtu tīru Trichomonas vaginalis kultūru, nepieciešama barotne. Kultūrdiagnostika sasniedzama, iesējot izmeklējamo materiālu trichomonu selektīvajā barotnē (Feinberga modifikācija), kurā slāpekļa avots ir aknu substrāts. Barotnei pievieno dekstrāzi, nātrija hlorīdu un agaru, kā arī antibiotikas (penicilīnu un streptomicīnu), kas aizkavē blakusmikrobu augšanu; Minētā barotne ir izgudrojuma prototips (4).A culture is required to obtain a pure culture of Trichomonas vaginalis. Culture diagnosis can be achieved by seeding the test substance in a trichomonous selective medium (Feinberg's modification), in which the nitrogen source is the liver substrate. Dextrase, sodium chloride and agar are added to the medium as well as antibiotics (penicillin and streptomycin) which inhibit the growth of side-germs; This medium is a prototype of the invention (4).
Prototipa barotnes viena litra sastāvs:Composition of one liter of prototype medium:
aknu substrāts dekstrāze nātrija hlorīds g 5 ghepatic substrate dextrase sodium chloride g 5 g
6,5 g 1 g līdz 1000 ml agars destilēts ūdens6.5 g 1 g to 1000 ml agar distilled water
Pēc barotnes autoklavēšanas ( 20 min. pie 0,5 atmosfērām) un atdzesēšanas līdz 50° C. Pirms lietošanas pievieno 30 ml zirga asins serumu, kā arī 1000 vienību pencilīnu un 500 mkg streptomicīnu uz vienu ml barotnes.After autoclaving the medium (20 min at 0.5 atmospheres) and cooling to 50 ° C, 30 ml of horse blood serum, 1000 units of pencillin and 500 mcg of streptomycin per ml of medium are added before use.
Šī barotne plaši tiek pielietota uro^enitālās trichomoniāzes kultūrdiagnostikā. Trichomonu augšana barotnē liecina par to, ka Trichomonas vaginalis ir cēlonisks faktors izraisītai slimībai.This medium is widely used in the cultural diagnosis of urinary trichomoniasis. Growth of Trichomonas in culture indicates that Trichomonas vaginalis is a causative factor for the disease caused.
Izgudrojuma mērķis ir jaunas barotnes radīšana, kura lautu paātrināt Trichomonas vaginalis kultūras vairošanos un pirms barotnes pielietošanas laboratorijas apstākļos vienkāršotu tās sagatavošanas tehnoloģiju.The object of the invention is to create a new medium which would allow to accelerate the growth of Trichomonas vaginalis culture and to simplify the technology of its preparation before use of the medium under laboratory conditions.
Uzstādītais mērķis sasniedzams tādējādi, ka lai izaudzētu Trichomonas vaginalis tiek izmantota barotne, saturoša slāpekļa avotu, dekstrāze, streptomicīnu, pencilīnu, dzīvnieku asins serumu un destilētu ūdeni, pie tam tā papildus satur askorbinskābi, citronskābi, orota skābi, pienskābes kalciju, amfoglukamīnu, kā slāpekļa avotu izmanto olu pulveri pēc lizocima izdalīšanas, sekojošās komponentu attiecībās, g/1:The stated objective is achieved by using a culture medium containing nitrogen source, dextrase, streptomycin, pencillin, animal blood serum and distilled water for growth of Trichomonas vaginalis, additionally containing ascorbic acid, citric acid, orotonic acid, lactic acid calcium, source uses egg powder after lysozyme extraction, in the following component ratios, g / 1:
olu pulveris pēc lizocima izdalīšanas 13-15 askorbinskābe 0,5-0,7 citronskābe 0,11-0,13egg powder after lysozyme extraction 13-15 ascorbic acid 0,5-0,7 citric acid 0,11-0,13
-3orota skābe pienskābes kalcijs dekstrāze streptomicīns pencilīns amfoglukamīns dzīvnieku asins serums destilēts ūdens līdz Barotnes pH-3orotinic acid lactic acid calcium dextrase streptomycin pencillin amphoglucamine animal blood serum distilled water to pH
0,07 - 0,08 0,9 - 1,1 5,0 - 7,0 0,9 - 1,10.07 - 0.08 0.9 - 1.1 5.0 - 7.0 0.9 - 1.1
900 000 - 1.100 000 vien. 39 000 - 41 000 vien.900,000 - 1,100,000 alone 39,000 - 41,000 alone
199 - 201 ml199-201 ml
- 1 litram- 1 liter
6,0 - 6,56.0 - 6.5
Jauna barotne ļauj paātrināt Trichomonas vaginalis kultūras vairošanos.A new culture allows for accelerated growth of Trichomonas vaginalis culture.
Barotnes - prototipu un trīs variantus jaunradīto barotni sterilos apstākļos salej 30 bakterioloģiskos stobriņos (pa 5 ml katrā). Izmeklējamo materiālu vienādos daudzumos (0,5 ml frichomonu kultūras) ievieto visos ar barotni esošos stobriņos. Kultūru audzē pie temperatūras 34-35° C. Uzsējumus uzskaita kultivēšanas 1.-3., 5.-7. un 9.-11. diennakti.Media: Prototype media and three variants of the new medium are placed under sterile conditions in 30 bacteriological tubes (5 ml each). Equal volumes of test material (0.5 ml of the culture medium of the frichomons) are placed in all tubes in the culture medium. The culture is grown at 34-35 ° C. The inocula are listed in culture sections 1-3, 5-7. and 9-11. around the clock.
Atzīmē un vērtē Trichomonu parādīšanās laiku, augšanas intensitāti, Trichomonu mobilitāti un morfoloģiju. Trichomonu pētījumi tiek veikti tās mikroskopājot tumšās redzes laukā.Trichomon onset, growth rate, Trichomon mobility and morphology are noted and evaluated. Trichomon studies are performed under the microscope of the microscope in the dark field of vision.
Trichomonu augšanas intensitāti vērtē pēc ballu sistēmas:Trichomon growth rate is evaluated by a scoring system:
Trichomonu i ml barotnes,Trichomonas per ml medium,
Trichomonu mobilitāte vērtēta pēc 4 + sistēmas :Trichomon mobility assessed by 4+ system:
+ - Trichomonas redzes laukā nepārvietojas, kustas tikai to viciņas;+ - does not move in the field of view of Trichomonas, only their pennants move;
+ - Trichomonu ķermenis un to viciņas aktīvi kustas;+ - The body of the Trichomons and their scabs are actively moving;
+ - aktīvi kustas Trichomonu viciņas un pārvietojas to ķermenis;+ - Trichomon puppets are actively moving and their bodies are moving;
+ - Trichomonas aktīvi pārvietojas un izkļūst no mikroskopa redzes lauka ietvariem.+ - Trichomonas actively moves in and out of the microscope's field of view.
Trichomonu morfoloģija tika izvērtēta mikroskopiski. Izmantojot mikroskopēšanu tumšā redzes laukā.Vērota Trichomonu formu dažādība, to vairošanos un kustību īpatnības.Trichomon morphology was evaluated microscopically. Using microscopy in the dark field of vision. Trichomonous forms were observed, their reproduction and movement characteristics were observed.
-4Trichomonu augšana barotnē - prototips.-4Trichomone growth in culture medium - prototype.
Vērtējums. Pirmajā diennaktī Trichomonas savairojās (pozitīvs rezultāts) 5 barotnes, otrā diennaktī - 10 barotnes, trešā diennaktī - 9 barotnes, ceturtā diennaktī 2 barotnēs, piektā diennaktī - 1 barotnē, septītā diennaktī - 1 barotnē, devītā diennaktī - 1 barotne, vienpadsmitā diennaktī - 1 barotne.Evaluation. Trichomonas multiplied (positive result) on day 1, 5 media, second day on 10 media, third day on 9 media, fourth day on 2 media, fifth day on media 1, seventh day on media 1, day 1 and day 1, feed.
Trichomonu augšanas intensitāte:Trichomon growth rate:
bail. - 3, bail. - 7, bail. - 5, bail. - 10, bail. - 5.bail. - 3, bail. - 7, bail. - 5, bail. - 10, bail. - 5.
Trichomonu mobilitāte:Trichomon Mobility:
1+ - 2;1+ to 2;
2+ - 7;2+ - 7;
3+ - 12;3+ - 12;
4+ - 9.4+ - 9.
Trichomonu morfoloģija bija tipiska.Trichomon morphology was typical.
Jaunizveidotās barotnes 1.piemērs.Example 1 of a newly created medium.
Barotni gatavo, ievērojot tās komponentu sekojošas attiecības, grami/litrā:The medium shall be prepared in the following proportions of its components, in grams per liter:
pH vide 6,0pH 6.0
Vērtējums. Pirmajā diennaktī pozitīvs rezultāts 28 barotnēs, otrā diennaktī - 2 barotnēs.Evaluation. Positive result on the first day in 28 media and on the second day in 2 media.
Trichomonu augšanas intensitāte:Trichomon growth rate:
bail. - 2;bail. - 2;
Trichomonu mobilitāte:Trichomon Mobility:
2+ - 5;2+ to 5;
3+ - 17;3+ - 17;
4+ - 8.4+ - 8.
Trichomonu morfoloģija barotnē - prototips un jaunradītajā barotnē bija tipiska.The morphology of Trichomons in the medium - prototype and in the newly created medium was typical.
Jaunizveidotās barotnes 2.piemērs.Example 2 of a newly created medium.
Barotni gatavo ar sekojošām tās sastāvdaļām, g/l:The medium is prepared with the following ingredients, g / l:
olu pulveris pēc lizocīma izdalīšanas - 14,0 askorbīnskābe - 0,6 citronskābe - 0,l2 orota skābe - 0,075 pienskābes kalcijs - 1,0 dekstrāze - 6,0 streptomicīns -1,0 pencilīns - 1000 000 vien.egg powder after lysozyme excretion - 14.0 ascorbic acid - 0.6 citric acid - 0.12 orotonic acid - 0.075 lactic acid calcium - 1.0 dextrase - 6.0 streptomycin -1.0 pencillin - 1000 000 units.
amfoglukomīns - 40 000 vien.amphoglucomine - 40,000 units.
zirgu vai liellopu asins serums - 200ml destilēts ūdens līdz - 1 litram pH 6,3horse or bovine serum - 200 ml distilled water to - 1 liter pH 6.3
Vērtējums. Pirmaja diennakti pozitīvi rezultāti 30 stobriņos. Augšanas intensitāte:Evaluation. First round positive results in 30 tubes. Growth intensity:
Mobilitāte: 2+ - 1;Mobility: 2+ - 1;
3+ - 20;3+ to 20;
4+ - 9.4+ - 9.
Morfoloģija: tipiska.Morphology: typical.
6Jaunizveidotas barotnes 3.piemers.6Examples of Newly Created Feeds 3.
Barotni gatavo ar sekojošām tās sastāvdaļām, g/1:The medium is prepared with the following ingredients, g / 1:
olu pulveris pēc lizocima izdalīšanas askorbīnskābe citronskābe orota skābe pienskābes kalcijs dekstrāze streptomicīns pencilīns amfoglukamīns zirga vai liellopa asins serums destilēts ūdens līdzegg powder after lysozyme excretion ascorbic acid citric acid orotic acid lactic acid calcium dextrase streptomycin pencillin amphoglucamine horse or bovine serum distilled water to
- 15,0- 15.0
- 0,7- 0.7
- 0,13- 0.13
- 0,08 - 1,1- 0.08 - 1.1
- 7,0- 7.0
- 1,1- 1.1
1.100 000 vien. 41 000 vien.1,100,000 alone 41,000 units
201 ml litram ptt vide 6,5201 ml per liter ptt medium 6.5
Vērtējums. Pirmajā diennakti pazitivi rezultāti 30 stobriaos.Evaluation. In the first 24 hours positive results in 30 stobriaos.
Augšanas intensitāte:Growth intensity:
bail. - 4;bail. - 4;
bail. - 3;bail. - 3;
bail. - 15;bail. - 15;
bail. - 8.bail. - 8.
Mobilitāte:Mobility:
2+ - 2;2+ to 2;
3+ - 21;3+ - 21;
4+ - 7.4+ - 7.
Morfoloģija: tipiska.Morphology: typical.
Jaunradītā Trichomonas vaginalis kultivēšanas barotne uzlabo inficētu slimnieku atklāsmi:The newly developed culture medium for Trichomonas vaginalis improves the detection of infected patients:
izmeklējot 100 pacientu ar barotni - prototipu atklāti 12 inficēti pacienti, ar jaunradīto barotni tai pašai slimnieku grupai - 17 inficēti pacienti.Investigation of 100 patients with medium - 12 infected patients were detected in the prototype, and 17 infected patients with the newly created medium for the same group of patients.
Jaunradīta barotne ļauj uzlabot Trichomonas vaginalis kultūras augšanu, kas palielina pozitīvu rezultātu diagnosticējot saslimšanu.The newly created medium allows for improved growth of Trichomonas vaginalis culture, which increases the positive result in the diagnosis of the disease.
Bez tam barotnei nav vajadzīga autoklavēšana, kas vienkāršo tās sagatavošanas tehnoloģiju laboratorijas apstākļos.In addition, the culture does not require autoclaving, which simplifies its preparation technology under laboratory conditions.
Barotne ir ekonomiska, tā kā tās sastāvā izmanto lizocima ražošanas atkritumus.The medium is economical because it uses waste from lysozyme production.
IZMANTOTA LITERATŪRALITERATURE USED
1. U.F.Haustein Sexuell ubertragbare Kronkheitena - Gustav Fischer Verlag Jena, 1990.-S.257 - 263.1. U.F. Haaustin Sexuell ubertragbare Kronkheitena - Gustav Fischer Verlag Jena, 1990.-S.257-263.
2. P.Vasariaš, A.Miltiuš - Dermatoveneroloģija ģimene ārstiem - Rīga: Zvaigzne, 1993- 4.p. 366 - 368.2. P.Vasariaš, A.Miltiuš - Dermatovenerology for Family Physicians - Riga: Zvaigzne, 1993- 4.p. 366 - 368.
3. A.Miltiaš - Ierīce cauruļveida orgānu satura izlemšanai II Latvijas patents uz izgudrojumu LV 10905 B, int.Cl^3. A.Miltiash - Device for determining the content of tubular organs II Latvian patent for the invention EN 10905 B, int.Cl ^
A 61 B 10/00. Pieteikuma datums 1994.gada 2.jūnijā, patenta publikācijas datums 1996.gada 20.aprīlī.A 61 B 10/00. Date of application: June 2, 1994, Date of publication of the patent: April 20, 1996.
4. E.Van Dyck, P.Piot, A.Meheus. Bench - Ievel laboratory manual for sexunally transmitted diseases - Geneva:4. E. Van Dyck, P.Piot, A. Meheus. Bench - Ievel laboratory manual for sexunally transmitted diseases - Geneva:
WH0/ VOT/89, 443. - P.55-56.WH0 / VOT / 89, 443. - P.55-56.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-97-12A LV11869B (en) | 1997-01-29 | 1997-01-29 | Culture medium for trichomonas vaginalis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-97-12A LV11869B (en) | 1997-01-29 | 1997-01-29 | Culture medium for trichomonas vaginalis |
Publications (2)
Publication Number | Publication Date |
---|---|
LV11869A LV11869A (en) | 1997-10-20 |
LV11869B true LV11869B (en) | 1998-01-20 |
Family
ID=19736260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-97-12A LV11869B (en) | 1997-01-29 | 1997-01-29 | Culture medium for trichomonas vaginalis |
Country Status (1)
Country | Link |
---|---|
LV (1) | LV11869B (en) |
-
1997
- 1997-01-29 LV LVP-97-12A patent/LV11869B/en unknown
Also Published As
Publication number | Publication date |
---|---|
LV11869A (en) | 1997-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Grooters | Pythiosis, lagenidiosis, and zygomycosis in small animals | |
Romanova et al. | Microbial communities on kidney stones | |
Rodriguez et al. | Consequences of intrauterine enrofloxacin infusion on mare endometrium | |
Schleig et al. | Attachment of Mycobacterium avium subspecies paratuberculosis to bovine intestinal organ cultures: method development and strain differences | |
FR2518408A1 (en) | COMPOSITION FOR INTIMATE FEMALE HYGIENE, ESPECIALLY FOR VAGINAL SHOWERS | |
Wicky et al. | Radiological findings in nine AIDS patients with Rhodococcus equi pneumonia | |
Rosen et al. | Persistent viability of the Medlar body | |
Justesen et al. | Anaerobic infections in chronic prostatitis and chronic urethritis | |
LV11869B (en) | Culture medium for trichomonas vaginalis | |
ROBERTSON et al. | Thoracic empyema in the dog; a report of twenty‐two cases | |
RU2759831C1 (en) | Nutrient medium for cultivating microorganisms from burkholderia cepacia complex | |
Rovay et al. | Update on treatment of vesiculitis in bulls | |
RU2569456C1 (en) | Nutrient medium for detection of necrobacillosis pathogen | |
CN107043802B (en) | Methods and media for enhanced detection of mycobacteria | |
Koiter et al. | Regulation of the bacterial microflora of the vagina in cyclic female rats | |
JP2000500321A (en) | Method and apparatus for testing antimicrobial susceptibility of paraffin-philic microorganisms | |
RU2249821C1 (en) | Method for estimating vaginal microbiocenosis | |
RU2642327C1 (en) | Method for prediction of pathogenetic process development for non-cultured or cultured type in experiment | |
Alwan et al. | Comparing the effect of some plant extracts and commercial washes against some isolated microorganisms from vagina of pregnant women | |
Ali et al. | Antibiotic and virulence profile of UTIs associated bacteria | |
Ilgekbayeva et al. | Biological characteristics of Rhodococcus equi isolated in the Republic of Kazakhstan | |
RU2353654C1 (en) | Method of isolating plague microbe by bacteriological method from investigated material (versions) | |
Karigoudar et al. | Trichomonas tenax: A rare cause of pleural effusion. | |
RU2392624C1 (en) | Differential diagnostcs of purulent cholangitis method | |
Мусаева et al. | CHARACTERISTICS OF BACTERIAL MICROFLORA IN RATS WITH MASSIVE INFECTION OF THE ABDOMINAL CAVITY |